Vinay M.,Aix - Marseille University |
Franche N.,Aix - Marseille University |
Gregori G.,Aix - Marseille University |
Fantino J.-R.,Aix - Marseille University |
And 2 more authors.
PLoS ONE | Year: 2015
Water safety is a major concern for public health and for natural environment preservation. We propose to use bacteriophages to develop biosensor tools able to detect human and animal pathogens present in water. For this purpose, we take advantage of the highly discriminating properties of the bacteriophages, which specifically infect their bacterial hosts. The challenge is to use a fluorescent reporter protein that will be synthesized, and thus detected, only once the specific recognition step between a genetically modified temperate bacteriophage and its bacterial host has occurred. To ensure the accuracy and the execution speed of our system, we developed a test that does not require bacterial growth, since a simple 1-hour infection step is required. To ensure a high sensitivity of our tool and in order to detect up to a single bacterium, fluorescence is measured using a portable flow cytometer, also allowing on-site detection. In this study, we have constructed and characterized several "phagosensor" prototypes using the HK620 bacteriophage and its host Escherichia coli TD2158 and we successfully adapted this method to Salmonella detection. We show that the method is fast, robust and sensitive, allowing the detection of as few as 10 bacteria per ml with no concentration nor enrichment step. Moreover, the test is functional in sea water and allows the detection of alive bacteria. Further development will aim to develop phagosensors adapted on demand to the detection of any human or animal pathogen that may be present in water. Copyright © 2015 Vinay et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Source
Pherecydes Pharma | Date: 2010-04-27
The present invention relates to a method for the reversible immobilization of lytic bacteriophages within their modified bacterial hosts. It relates more particularly to a method for modifying the genome of a lytic bacteriophage by immobilizing said bacteriophage in the host bacterium thereof.
Pherecydes Pharma | Entity website
The bacteriophage is the most ubiquitous (numerous) biological species on Earth. Phages are present in all aquatic and terrestrial environments (and so called natural) ...
Pherecydes Pharma | Entity website
A world first: Pherecydes Pharma launches multicenter clinical study of phage therapy in serious burFor the first time, an industry-standard clinical trial is evaluating the tolerance and effectiveness of phages in fighting sensitive antibiotic-resistant infectionsPublication 15/06/2015French Documentary on FUTUR MAG - ARTEA documentary about Pherecydes Pharma and its products to treat burned patients ( Phagoburn project ) was released February 7, 2015 in Future mag on the Arte channel.Article in LesEchos ...
Rapid identification of international multidrug-resistant Pseudomonas aeruginosa clones by multiple-locus variable number of tandem repeats analysis and investigation of their susceptibility to lytic bacteriophages
Larche J.,Center Hospitalier Of Narbonne |
Pouillot F.,Pherecydes Pharma |
Essoh C.,University Paris - Sud |
Essoh C.,French National Center for Scientific Research |
And 12 more authors.
Antimicrobial Agents and Chemotherapy | Year: 2012
The objective of this study was to determine the genetic diversity of multidrug-resistant (MDR) Pseudomonas aeruginosa strains isolated over a period of 12 months in two French hospitals and to test their susceptibility to bacteriophages. A total of 47 MDR isolates recovered from hospitalized patients were genotyped using multiple-locus variable number of tandem repeats analysis. The genotypes were distributed into five clones (including 19, 5, 5, 3, and 3 isolates, respectively) and 12 singletons. Comparison to 77 MDR strains from three other countries, and MLST analysis of selected isolates showed the predominance of international MDR clones. The larger clone, CC235, contained 59 isolates displaying different antibiotic resistance mechanisms, including the presence of the GES1, VIM-2, VIM-4, and IMP-1 β-lactamases. Three newly isolated P. aeruginosa bacteriophages were found to lyse 42 of the 44 analyzed strains, distributed into the different clonal complexes. This pilot study suggests that systematic genotyping of P. aeruginosa MDR strains could improve our epidemiological understanding of transmission at both the local (hospital) and the national level and that phage therapy could be an alternative or a complementary treatment to antibiotics for treating MDR-infected patients. Copyright © 2012, American Society for Microbiology. All Rights Reserved. Source